{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"252","upperLimit":"1320","value":"755"},{"groupId":"OG001","lowerLimit":"816","upperLimit":"1910","value":"1111"},{"groupId":"OG002","lowerLimit":"1074","upperLimit":"2349","value":"1147"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"The median (min, max) of the total area under the plasma concentration curve of entinostat stratified by study part, dose level. Time points were assessed at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1.","dispersionType":"Full Range","groups":[{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 3 mg/m2","id":"OG000","title":"Stratum 1 With 3 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 4 mg/m2","id":"OG001","title":"Stratum 1 With 4 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors without bone marrow involvement, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at the RP2D (4 mg/m2)","id":"OG002","title":"PK Part With 4 mg/m²"}],"paramType":"MEDIAN","populationDescription":"All eligible enrolled patients.","reportingStatus":"POSTED","timeFrame":"Up to 96 hours","title":"Total Area Under the Plasma Concentration Curve of Entinostat: AUC","type":"PRIMARY","unitOfMeasure":"hr*ng/mL"}